Cadrenal to seek FDA rare pediatric disease designation for tecarfarin in Kawasaki disease

Cadrenal Therapeutics announced plans to submit a Rare Pediatric Disease Designation request to the FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms. Approval could qualify the company for a Priority Review Voucher valued around $200 million, providing significant financial upside.